Vasodilator Effect of Glucagon: Receptorial Crosstalk Among Glucagon, GLP-1, and Receptor for Glucagon and GLP-1

被引:21
|
作者
Selley, E. [1 ,2 ]
Kun, S. [1 ,2 ]
Szijarto, I. A. [3 ,4 ]
Kertesz, M. [1 ,2 ]
Wittmann, I. [1 ,2 ]
Molnar, G. A. [1 ,2 ]
机构
[1] Univ Pecs, Dept Med 2, Pecs, Hungary
[2] Univ Pecs, Nephrol Ctr, Pecs, Hungary
[3] Charite Campus Virchow Klinikum, Med Clin Nephrol & Internal Intens Care, Berlin, Germany
[4] Max Delbruck Ctr Mol Med, ECRC, Berlin, Germany
关键词
aortic rings; glucagon; GLP-1; vasodilatation; INSULIN-INDUCED RELAXATION; SMOOTH-MUSCLE-CELLS; FATTY LIVER-DISEASE; ANTIDIABETIC AGENTS; MECHANISM; ARTERIES; SECRETION; CHANNELS; INCREASE; INJURY;
D O I
10.1055/s-0042-101794
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glucagon is known for its insulin-antagonist effect in the blood glucose homeostasis, while it also reduces vascular resistance. The mechanism of the vasoactive effect of glucagon has not been studied before; thereby we aimed to investigate the mediators involved in the vasodilatation induced by glucagon. The vasoactive effect of glucagon, insulin, and glucagon-like peptide-1 was studied on isolated rat thoracic aortic rings using a wire myograph. To investigate the mechanism of the vasodilatation caused by glucagon, we determined the role of the receptor for glucagon and the receptor for GLP-1, and studied also the effect of various inhibitors of gasotransmitters, inhibitors of reactive oxygen species formation, NADPH oxidase, prostaglandin synthesis, protein kinases, potassium channels, and an inhibitor of the Na+/Ca2+-exchanger. Glucagon causes dose-dependent relaxation in the rat thoracic aorta, which is as potent as that of insulin but greater than that of GLP-1 (7-36) amide. Vasodilatation by GLP-1 is partially mediated by the glucagon receptor. The vasodilatation due to glucagon evokes via the glucagon-receptor, but also via the receptor for GLP-1, and it is endothelium-independent. Contribution of gasotransmitters, prostaglandins, the NADPH oxidase enzyme, free radicals, potassium channels, and the Na+/Ca2+ -exchanger is also significant. Glucagon causes dose-dependent relaxation of rat thoracic aorta in vitro, via the receptor for glucagon and the receptor for GLP-1, while the vasodilatation evoked by GLP-1 also evolves partially via the receptor for glucagon, thereby, a possible crosstalk between the 2 hormones and receptors could occur.
引用
收藏
页码:476 / 483
页数:8
相关论文
共 50 条
  • [1] Glucagon, GLP-1 and Thermogenesis
    Gonzalez-Garcia, Ismael
    Milbank, Edward
    Dieguez, Carlos
    Lopez, Miguel
    Contreras, Cristina
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (14)
  • [2] Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure
    Bagger, Jonatan Ising
    Holst, Jens Juul
    Hartmann, Bolette
    Andersen, Birgitte
    Knop, Filip Krag
    Vilsboll, Tina
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (12): : 4541 - 4552
  • [3] Glucagon-like peptide 1 (GLP-1)
    Mueller, T. D.
    Finan, B.
    Bloom, S. R.
    D'Alessio, D.
    Drucker, D. J.
    Flatt, P. R.
    Fritsche, A.
    Gribble, F.
    Grill, H. J.
    Habener, J. F.
    Holst, J. J.
    Langhans, W.
    Meier, J. J.
    Nauck, M. A.
    Perez-Tilve, D.
    Pocai, A.
    Reimann, F.
    Sandoval, D. A.
    Schwartz, T. W.
    Seeley, R. J.
    Stemmer, K.
    Tang-Christensen, M.
    Woods, S. C.
    DiMarchi, R. D.
    Tschoep, M. H.
    MOLECULAR METABOLISM, 2019, 30 : 72 - 130
  • [4] Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
    Seghieri, Marta
    Christensen, Alexander S.
    Andersen, Andreas
    Solini, Anna
    Knop, Filip K.
    Vilsboll, Tina
    FRONTIERS IN ENDOCRINOLOGY, 2018, 9
  • [5] Glucagon Stimulates Insulin Secretion through Both Glucagon and GLP-1 Receptors
    Encisco, Sara
    Svendsen, Berit
    D'Alessio, David A.
    Campbell, Jonathan
    DIABETES, 2017, 66 : A584 - A584
  • [6] Oxyntomodulin (GLP-1/glucagon) and GLP-1 on Body Weight, Glucose Metabolism and Renal Function
    Pocai, Alessandro
    OBESITY, 2023, 31 : 87 - 87
  • [7] Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids
    Suschak, John J.
    Georges, Bertrand
    Roberts, M. S.
    Harris, M. Scott
    Browne, Sarah K.
    DIABETES, 2024, 73
  • [8] Combining GLP-1 and glucagon for the treatment of obesity and diabetes
    Idris, Iskandar
    DIABETES OBESITY & METABOLISM, 2013, 15 (05): : 481 - 482
  • [9] Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists
    Jiang, Neng
    Jing, Lin
    Li, Qing
    Su, Sibiao
    Yang, Qimeng
    Zhou, Feng
    Chen, Xinyu
    Han, Jing
    Tang, Chunli
    Tang, Weizhong
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 212
  • [10] GLP-1/glucagon receptor co-agonism for treatment of obesity
    Miguel A. Sánchez-Garrido
    Sara J. Brandt
    Christoffer Clemmensen
    Timo D. Müller
    Richard D. DiMarchi
    Matthias H. Tschöp
    Diabetologia, 2017, 60 : 1851 - 1861